1 / 4

Proposed R01 submission to the National Institutes of Health

Proposed R01 submission to the National Institutes of Health. Preliminary Data. Blood Aβ data from Nilvadipine ph I /II (Aβ40 increased in AD) Aβ40 reduced with treatment (E3>E4) (SM reduced, ceramide increased in AD) SM increased with treatment Ongoing (progression data)

winter
Download Presentation

Proposed R01 submission to the National Institutes of Health

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Proposed R01 submission to the National Institutes of Health

  2. Preliminary Data Blood Aβ data fromNilvadipine ph I/II (Aβ40 increased in AD) Aβ40 reduced with treatment (E3>E4) (SM reduced, ceramide increased in AD) SM increased with treatment Ongoing (progression data) miRNA in longitudinal trials lipidomicin longitudinal trials

  3. Specific Aims Aim 1:To examine blood/CSF Aβ and tau/p-tau in repsonse to treatment in the phase III nilvadipine trial in AD. Aim 2: To examine miRNA and phospholipids as biomarkers of AD progression in the phase III nilvadipine trial of AD. Aim 3: To determine if apolipoprotein (APOE)-genotype dependent modification of treatment response to nilvadipine is detectable by in this biomarker panel. Aim 4: ? Correlation of biomarker response with other markers ie imaging etc.

  4. Specific Aims Aim 1: To correlate Aβ and tau levels in cerebrospinal fluid (CSF) and/or blood with therapeutic response in the phase I/IIanilvadipine trial of AD. Aim 2: To use miRNA in cerebrospinal fluid (CSF) and/or blood for detecting therapeutic response in phase I/IIanilvadipine trial of AD Aim 3: To use phospholipids in cerebrospinal fluid (CSF) and/or blood for detecting therapeutic response in phase I/IIanilvadipine trial of AD.

More Related